
The fellowship begins Jand ends June 30, 2025.

#DAY ONE BIOPHARMACEUTICALS TRIAL#
is engaged in developing and commercializing targeted therapies for patients. Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma Day One Biopharmaceuticals, Inc. Founded to tackle the lack of treatment options in pediatric cancer, Day Ones name reflects its mission to redefine the day one talk clinicians have with. The Day One Biopharmaceuticals annual revenue is estimated at < 1M. Through hands-on experience, the fellow will become familiar with protocol design, scientific oversight of trials, interpretation and reporting of study results results, and more. Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. The number of employees ranges from 1 to 25. The fellow will contribute to the scientific aspects of Day One’s oncology clinical programs, with opportunities spanning Phases I – III. The Clinical Science team at Day One supports our mission of delivering new therapies to those with the greatest unmet need by execution of clinical development plans with the highest level of integrity and urgency. Day One Biopharmaceuticals - email id & phone of 1 top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company.
